Calliditas Therapeutics IPO Presentation Deck slide image

Calliditas Therapeutics IPO Presentation Deck

Rationale and next steps Plan to rapidly develop and seek approval and commercialize in U.S. • AIH PBC Creates optionality and flexibility for product portfolio in the U.S. Orphan indication with market exclusivity and reimbursement • No approved treatments in the U.S. calliditas ■ • Differentiated approach targeting reduction in both inflammation and origin of auto immune response Preparation for FDA interaction initiated • FDA interaction targeted for 2020 for AIH and 1Q 2021 for PBC June 2020 30
View entire presentation